Unfortunately, and given that we used a large collection of drugs covering most biological pathways, our results suggest that the chemical-induction of HLA-I expression in cancer cells harboring mutations that disable IFNγ signaling is unlikely to succeed. The gene discussed is IFNG; the disease is cancer.